Hepatic Cancer

Cotara phase I hepatic cancer study published in cancer journal

Published in Cancer Weekly, March 2nd, 2004

Peregrine Pharmaceuticals (PPHM) announced that phase I data from its Cotara hepatic cancer study was published in Cancer Therapy.

The data from the study highlights the utility of Cotara when used in combination with radiofrequency ablation (RFA) in the treatment of hepatic cancer metastases.

Cotara is Peregrine's radiolabeled tumor necrosis therapy (TNT) targeting monoclonal antibody. Cotara has received approval from the U.S. Food and Drug Administration to start a registration clinical trial for brain cancer in the U.S.

Radiolabeled TNT has received marketing approval for the treatment of advanced lung cancer in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-03-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry